DUAVIVE (conjugated estrogens and bazedoxifene modified release tablets) Indications And Clinical Use

Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

DUAVIVE (conjugated estrogens/bazedoxifene) is indicated in women with a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause.

DUAVIVE should not be taken with a progestin, additional estrogens or selective estrogen receptor modulators (SERMs) (see DOSAGE AND ADMINISTRATION, Dosing Considerations)

Geriatrics (> 75 years of age):

DUAVIVE has not been studied in women over 75 years of age, therefore DUAVIVE is not recommended for women over 75 years of age (see CLINICAL TRIALS, Geriatrics and ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics).


DUAVIVE is not indicated for pediatric use.